General Description

Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol.

Pharmacological Class

Hormone (human parathyroid hormone, recombinant).

Mechanism of Action

Teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.

Indications

Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see full labeling).

Adult

20mcg SC once daily into thigh or abdominal wall. Give supplemental calcium and vitamin D if daily intake is inadequate. Consider treating for more than 2 years only if patient remains at or has returned to having high risk for fracture.

Children

Not established.

HOT SELLING

Semaglutide CAS 910463-68-2

Tirzepatide CAS 2023788-19-2

Retatrutide CAS 2381089-83-2

Liaglutide CAS 204656-20-2

Octreotide CAS79517-01-4

Dulaglutide CAS 923950-08-7

LixisenatideAcetate CAS 320367-13-3

Teduglutide CAS 197922-42-2

Albiglutide CAS 782500-75-8

Degarelix CAS 214766-78-6

Cilengitide CAS 188968-51-6

Mifamurtide CAS 83461-56-7

Somatostatin CAS 51110-01-1

Exenatide Acetate CAS 141732-76-5

Pramlintide CAS 151126-32-8

Eptifibatide CAS 188627-80-7

Bivalirudin CAS 128270-60-0

Semax CAS 80714-61-0